Lilly breaks ground on $6.5B Houston plant for Foundayo
Eli Lilly broke ground in Houston to expand factory capacity for Foundayo, its newly launched obesity pill, and CEO Dave Ricks said the drug has won one-third of new GLP-1 pill starts. The company is also targeting market share versus Novo Nordisk in oral obesity drugs.
Eli Lilly & Company (LLY) broke ground on a new facility in Houston on Monday as it adds more manufacturing capacity for Foundayo, its newly launched obesity pill. The company is aiming to take market share from rival Novo Nordisk (NVO) in the oral obesity drug market. Chair and CEO Dave Ricks told CNBC that…